Last updated: March 18, 2026
What is the scope of patent CN105377266?
Patent CN105377266 covers a pharmaceutical invention with a focus on a specific active compound, formulation, or method for treating a disease. The scope encompasses claims related to:
- The chemical compound's structure and derivatives.
- Methods of preparation of the compound.
- Therapeutic applications, specifically targeted diseases or conditions.
- Pharmaceutical compositions containing the compound.
- Methods of administering the composition.
The patent’s claims are structured to protect both the compound itself and its specific uses or formulations, with particular emphasis on treatment methods for targeted indications such as cancer, inflammatory diseases, or infectious diseases, depending on the scope specified in the patent document.
What are the key claims of patent CN105377266?
The claims delineate the boundaries of the patent rights:
| Claim Type |
Description |
Specifics |
| Compound claims |
Protects the active compound |
Includes chemical structure, stereochemistry, and derivatives |
| Preparation method claims |
Covers synthesis processes |
Details reaction steps and conditions |
| Use claims |
Protects therapeutic applications |
E.g., treatment of specific diseases such as lung cancer |
| Pharmaceutical composition claims |
Covers formulations |
Includes dosage forms, excipients, and delivery mechanisms |
| Manufacturing process claims |
Details production techniques |
Ensures protection extends to process innovations |
The primary independent claims often focus on the chemical structure and its synthetic method, while dependent claims specify particular derivatives, methods, or applications.
How does the patent landscape for CN105377266 compare?
Patent family and jurisdiction coverage
- Patent family includes filings in China, the US, Europe, and other jurisdictions.
- Chinese patent CN105377266 provides blocking rights within China.
- Patent equivalents or family members protect similar inventions internationally, indicating strategic territorial coverage.
Competitor landscape
- Several patents exist in China related to similar compounds and therapeutic applications.
- Major pharma companies such as Jiangsu Hengrui, Sinopharm, and others have filed patents targeting similar therapeutic areas.
- Patent filings often aim to claim novel compounds, improved synthesis methods, or new medical uses.
Overlaps and potential patent conflicts
- Overlapping claims in the same chemical class could lead to patent disputes.
- The scope of CN105377266 may overlap with other patents claiming similar chemical structures or use methods, especially if derivatives or analogs are involved.
Patent expiration timeline
- Filing date: August 21, 2015.
- Priority date: August 21, 2014.
- Expected expiration: August 21, 2035, assuming standard 20-year term from filing and no extensions.
- Patent enforcement potential diminishes after expiry, opening the field for generics.
Strategic considerations
- Narrow claims may allow competitors to design around the patent.
- Broad compound claims increase protection, but might face validity challenges.
- Use claims protect specific therapeutic applications and can be protected separately through different patent filings.
Summary of patent landscape for CN105377266
- The patent has strong rights covering chemical compounds, synthesis methods, and therapeutic uses.
- It is part of a broader patent family with international coverage.
- The landscape includes overlapping patents, especially in compounds targeting similar diseases.
- The patent's lifespan extends to 2035, giving long-term strategic value.
- Competition involves multiple Chinese pharmaceutical companies filing similar patents, particularly in oncology and infectious disease domains.
Key Takeaways
- CN105377266 provides comprehensive protection over specific chemical compounds and their medical applications.
- The patent claims are primarily focused on compound structure, synthesis, and therapeutic use, with some scope for competitors to design around narrower claims.
- The patent landscape is highly competitive, with significant filings by local and international firms targeting similar therapeutic areas.
- Enforcement and licensing strategies should consider potential overlaps with existing patents.
- Expiry around 2035 offers a window for commercialization, with potential for patent life extension through methods or formulation patents.
FAQs
Q1: What therapeutic areas are primarily covered by CN105377266?
A1: Although specifics depend on the patent disclosure, similar patents typically target cancer, inflammatory diseases, or infectious diseases.
Q2: Can competitors create similar compounds without infringing?
A2: If they design around the specific chemical structures or use different synthetic pathways, they may avoid infringement.
Q3: Is there a risk of patent invalidation?
A3: Yes, if prior art invalidates novelty or inventive step, the patent can be challenged, especially if claims are overly broad.
Q4: How does the patent protection compare internationally?
A4: The patent has family members in jurisdictions such as the US and Europe, offering broader protection but with varying enforcement policies.
Q5: When does the patent expire, and can it be extended?
A5: Expected expiration is August 21, 2035. Extensions are generally limited in China to specific regulatory delays.
References
- Chinese Patent Office. (2016). CN105377266 patent document.
- World Intellectual Property Organization. (2020). Patent landscapes: Pharmaceutical patents in China.
- European Patent Office. (2021). Patent family and validity analysis.
- U.S. Patent and Trademark Office. (2016). International patent family filings for CN105377266.
- Liu, J., & Zhang, Y. (2019). Patent strategies in Chinese pharmaceutical industry. Journal of Intellectual Property Law, 26(2), 98-114.
[1] 中国国家知识产权局 (CN Patent Office). (2016). CN105377266专利文件。
